Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice
Authors' conclusion
This study provides a comprehensive overview of the implementation of targeted therapies (bDMARDs and tsDMARDs) in non-systemic JIA over the past decade, showing a rise in targeted therapies alongside a decrease in csDMARD prescriptions.
Study context
- Population
- Patients aged 0–18 years with non-systemic JIA, Wilhelmina Children's Hospital (largest pediatric rheumatology centre in the Netherlands), January 2012 to December 2023696 patients
- Participants
- 672 vs 720
- Exposure
- Biological disease-modifying antirheumatic drugs (bDMARDs) and tsDMARDs vs conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)
- bDMARDs and tsDMARDsn = 672
- csDMARDsn = 720
- Outcome
- Trends in initial prescriptions of targeted therapies (bDMARDs and tsDMARDs)
Methodological detailssingle-centre, prescription records, Market introduction dates of targeted therapies for JIA extracted from the European Medicines Agency (EMA) database
- Single-centre
- Prescription records
- Market introduction dates of targeted therapies for JIA extracted from the EMA database
Main finding
As reported in the abstract
Relative proportion of first prescriptions · 2012 to 2023
- bDMARDs and tsDMARDs, 2012
- 32.2%
- bDMARDs and tsDMARDs, 2023
- 62.7%
- csDMARDs, 2012
- 67.8%
- csDMARDs, 2023
- 34.3%
- TNF-alpha inhibitors, share of bDMARDs and tsDMARDs
- 79.3%
- JAKi, 2020
- 1.6%
- JAKi, 2023
- 5.9%
Observational data: associations, not effects.
Original publication
Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice. Pediatr Rheumatol Online J. Published 29 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →